This study aims to understand better the effective results from the IMELDA MO22223 P-trial (NCT00929240) and see if the anti-cancer therapies given during its follow-up time after study treatments were terminated possibly had an effect on efficacy results.
Study Type
OBSERVATIONAL
Enrollment
185
No intervention administered in this study.
Percentage of Participants Who Prematurely Withdrawn From Maintenance Therapy
Participants who had prematurely withdrawn from maintenance study treatment were reported. The retrospectively collected data was pooled with the data collected within the IMELDA (MO22223) P-trial to allow a statistically meaningful analysis.
Time frame: Up to 78 months
Percentage of Participants Who Received Further Anti-Cancer Therapies After Discontinuation of Study Treatment
Participants who received further anti-cancer therapies after discontinuation of study treatment were reported. The retrospectively collected data was pooled with the data collected within the IMELDA (MO22223) P-trial to allow a statistically meaningful analysis.
Time frame: Up to 78 months
Time From Last Maintenance Study Medication Start to Start of Further Anti-Cancer Therapy
Time from last maintenance study medication to the start of any further anti-cancer therapy was reported. The retrospectively collected data was pooled with the data collected within the IMELDA (MO22223) P-trial to allow a statistically meaningful analysis.
Time frame: Up to 78 months
Progression Free Survival (PFS)
PFS was defined as the time from start of the study to the first documented occurrence of disease progression. The retrospectively collected data was pooled with the data collected within the IMELDA (MO22223) P-trial to allow a statistically meaningful analysis.
Time frame: Up to 78 months
Overall Survival
Overall survival was defined as the interval between start of the study and the date of death from any cause. The retrospectively collected data was pooled with the data collected within the IMELDA (MO22223) P-trial to allow a statistically meaningful analysis.
Time frame: Up to 78 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Instituto Nacional de Cancer - INCa; Oncologia
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital de Caridade de Ijui; Oncologia
Ijuí, Rio Grande do Sul, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Amaral Carvalho
Jaú, São Paulo, Brazil
Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia
Santo André, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Hospital Santa Marcelina;Oncologia
São Paulo, São Paulo, Brazil
HOPITAL JEAN MINJOZ; Oncologie
Besançon, France
Chg de Chartres Hopital Louis Pasteur; Pneumologie
Chartres, France
...and 22 more locations